Date & Time
Wednesday, May 22, 2024, 2:15 PM - 3:15 PM
Name
110 Prostate Cancer Update for Corrections*
Description
Prostate cancer is the most common malignancy encountered in corrections. While screening guidelines are well standardized, therapy options have become increasingly more complicated. Active surveillance remains a reasonable therapy option while robotic surgery can be considered the default therapy of choice in terms of cost and long-term complications. Advances in radiation therapy have expanded treatment options and can reduce the number of off-site transports. The role of new therapeutics, including hormonal options and novel radiopharmaceuticals, will be discussed, along with their effect on physicians' treatment decisions and patient outcomes.
Learning Objectives
- Identify patients appropriate for PSA screening
- Review treatment options for patients with low, intermediate, and high-risk prostate cancer
- Discuss hypo fractionated radiation therapy
Level: Intermediate
Speakers